Global Health Ltd
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]
- Market Cap ₹ 30,669 Cr.
- Current Price ₹ 1,141
- High / Low ₹ 1,456 / 1,010
- Stock P/E 54.2
- Book Value ₹ 138
- Dividend Yield 0.04 %
- ROCE 19.7 %
- ROE 16.5 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 70.2% CAGR over last 5 years
Cons
- Stock is trading at 8.33 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE 500 BSE Healthcare Nifty 500 BSE Allcap BSE SmallCap Select Index
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,382 | 1,343 | 1,456 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 4,182 | |
| 1,081 | 1,218 | 1,283 | 1,309 | 1,250 | 1,709 | 2,073 | 2,466 | 2,806 | 3,263 | |
| Operating Profit | 301 | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 920 |
| OPM % | 22% | 9% | 12% | 13% | 14% | 21% | 24% | 25% | 24% | 22% |
| 45 | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 29 | 14 | |
| Interest | 14 | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 67 |
| Depreciation | 70 | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 205 |
| Profit before tax | 262 | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 661 |
| Tax % | 35% | 45% | 38% | 43% | 11% | 30% | 27% | 24% | 26% | |
| 170 | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 514 | |
| EPS in Rs | 35.10 | 6.78 | 10.44 | 7.36 | 5.81 | 7.75 | 12.16 | 17.81 | 17.92 | 19.13 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 19% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 38% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 37% |
| 1 Year: | 3% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 17% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 |
| Reserves | 976 | 1,136 | 1,246 | 1,300 | 1,333 | 1,565 | 2,375 | 2,852 | 3,333 | 3,654 |
| 165 | 456 | 787 | 929 | 931 | 1,109 | 1,122 | 802 | 718 | 945 | |
| 295 | 343 | 347 | 388 | 380 | 421 | 547 | 572 | 662 | 757 | |
| Total Liabilities | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,410 |
| 914 | 1,094 | 1,194 | 1,703 | 1,616 | 1,776 | 2,050 | 2,236 | 2,514 | 3,199 | |
| CWIP | 12 | 317 | 666 | 382 | 464 | 439 | 327 | 388 | 533 | 318 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| 559 | 573 | 570 | 581 | 615 | 930 | 1,720 | 1,656 | 1,716 | 1,890 | |
| Total Assets | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,410 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| 228 | 63 | 166 | 175 | 242 | 311 | 645 | 612 | 624 | |
| -241 | -69 | -249 | -87 | -239 | -421 | -342 | -441 | -721 | |
| -7 | 9 | 97 | -1 | -81 | 160 | 346 | -514 | -97 | |
| Net Cash Flow | -20 | 3 | 14 | 87 | -78 | 50 | 648 | -343 | -194 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 41 | 41 | 36 | 34 | 30 | 26 | 24 | 29 |
| Inventory Days | 28 | 26 | 26 | 43 | 42 | 36 | 35 | 32 | 28 |
| Days Payable | 92 | 124 | 142 | 147 | 138 | 90 | 114 | 90 | 81 |
| Cash Conversion Cycle | -45 | -56 | -75 | -67 | -62 | -24 | -52 | -34 | -24 |
| Working Capital Days | -23 | -33 | -18 | -31 | -48 | -20 | -37 | -32 | -21 |
| ROCE % | 6% | 6% | 5% | 15% | 17% | 20% | 20% |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 2m
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
19h - Announcement Under Regulation 30 of Listing Regulations for Earning Conference Call Transcript.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
5 Feb - Audio recording of Medanta Q3 and nine-months results earnings call held Feb 5, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 Feb - Newspaper Publication under Regulation 30 and 47 of Listing Regulations.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
4 Feb - Investor Presentation for the third quarter and nine months ended December 31, 2025 results of the Company.
Annual reports
Concalls
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Dec 2022TranscriptAI SummaryPPT
Hospital Count[1]
Global Health operates 6 hospitals under the "Medanta" brand in Gurugram, Indore, Ranchi, Lucknow, Patna and Noida. Spanning an area of 5.6 million sq. ft., they have 3,435 installed beds as on Sep 30, 2025. They provide healthcare services in over 30 medical specialties and engage 2,000+ doctors led by highly experienced department heads.